Influence of baseline bronchodilator reversibility and blood eosinophils on lung function in patients with asthma following omalizumab

J Allergy Clin Immunol Pract. 2024 Feb;12(2):512-514.e2. doi: 10.1016/j.jaip.2023.11.045. Epub 2023 Dec 8.

Authors

Thomas B Casale¹, Bradley E Chipps², Ahmar Iqbal³, Bongin Yoo³, Lauren A Millette³, Nicola A Hanania⁴

Affiliations

¹ Division of Allergy and Immunology Joy McCann Culverhouse Clinical Research Center, University of South Florida, Tampa, Fla.
² Capital Allergy & Respiratory Disease Center, Sacramento, Calif.
³ Genentech, Inc, South San Francisco, Calif.
⁴ Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas. Electronic address: hanania@bcm.edu.

PMID: 38070771
DOI: 10.1016/j.jaip.2023.11.045

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Asthmatic Agents* / therapeutic use
Asthma*
Bronchodilator Agents / therapeutic use
Eosinophils
Humans
Lung
Omalizumab / therapeutic use
Treatment Outcome

Substances

Omalizumab
Bronchodilator Agents
Anti-Asthmatic Agents